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being highly correlated to disease activity: CXCL10, TNFR2
and Galectin-9.5 We measured these proteins before and at dif-
ferent time points after aSCT to determine kinetics and correl-
ation to disease activity in the context of this intervention.
Values of creatine kinase were not elevated in the weeks before
aSCT and did not change after, indicating low correlation with
actual disease activity. CXCL10, TNFR2 and Galectin-9 were
elevated in the patients prior to the conditioning regimen, irre-
spective of maintenance treatment (ﬁgure 1A). After aSCT,
these three markers decreased over time in patients 1 and 2
with the most pronounced reduction in levels of Galectin-9 and
CXCL10. These levels remained low, even after full reconstitu-
tion of the immune system. In parallel, clinical scores improved
over time as shown in ﬁgure 1B. Pre-existent severe calcinosis
disappeared completely in patient 2 after aSCT4 but is still per-
sisting in patient 3. Importantly, only in this patient, CXCL10
and Galectin-9 levels remained elevated after aSCT.
In contrast to TNFR2, CXCL-10 and Galectin-9 are pro-
duced by immune and non-immune cells under inﬂammatory
conditions.6–9 As circulating immune cells are largely depleted
during aSCT, our data suggest that CXCL10 and Galectin-9 are
mainly produced by tissue cells or tissue inﬁltrating cells.
Therefore, even during profound immunosuppression these
markers may reveal ongoing disease activity in the tissues. This
is also supported by the observation that CXCL10 and
Galectin-9 levels dropped very gradually following aSCT in
patients 1 and 2 and mirrored clinical disease improvement.
In conclusion these data demonstrate that aSCT can induce
prolonged drug-free disease remission in refractory patients
with JDM with regards to the myositis. Furthermore, we show
that the proinﬂammatory signature as measured by TNFR2,
CXCL-10 and Galectin-9 leads to a differentiated response after
aSCT, with a marked decrease in the two patients with inactive
disease but persistent elevation in a patient with skin involve-
ment. Further studies are needed to determine the immuno-
pathogenic role of these proteins in JDM.
F Bellutti Enders,1,2 E M Delemarre,1 J Kuemmerle-Deschner,3
P van der Torre,1 N M Wulffraat,1 B P Prakken,1 A van Royen-Kerkhof,1,#
F van Wijk1
1Laboratory of Translational Immunology, Department of Pediatric Immunology,
University Medical Centre Utrecht, Utrecht, The Netherlands
2Division of Allergology, Immunology and Rheumatology, Department of Pediatrics,
University Hospital, Lausanne, Switzerland
3Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital
Tuebingen, Tuebingen, Germany
Correspondence to Dr A van Royen-Kerkhof, Laboratory of Translational
Immunology, Department of Pediatric Immunology, Wilhelmina Children’s Hospital,
University Medical Centre Utrecht, Utrecht, Room KC 03.063.0, Lundlaan 6, Utrecht
3584 EA, The Netherlands; a.vanroyen@umcutrecht.nl
FBE, EMD, AvR-K and FvW contributed equally.
Acknowledgements The patients in this study gave informed consent to
publication of the data. The authors thank Iris Haugg, Dr Julia Thomas and
Dr Sandra Hansmann for providing clinical data and laboratory results.
Contributors Substantial contributions to the conception or design of the work, or
the acquisition, analysis or interpretation of data; drafting the work or revising it
critically for important intellectual content; ﬁnal approval of the version published;
agreement to be accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are appropriately
investigated and resolved: FBE, EMD, FvW, AvR-K, NW, BP, PvdT, JK-D.
Funding Ettore e Valeria Rossi Foundation; Bas Foundation, The Netherlands;
ZonMw Veni grant from the Netherlands Organisation of Scientiﬁc Research (NWO);
ZonMw AGIKO grant from the NWO; Reumafonds, the Netherlands.
Competing interests FBE is supported by Swiss Grants (The foundation of Ettore
e Valeria Bossi). FBE is supported by the patient’s society (Bas Stichting). FvW is
supported by a ZonMw Veni grant from the Netherlands Organisation of Scientiﬁc
Research (NWO). EMD is supported by a ZonMw AGIKO grant from the NWO. NW
and BP are supported by the Reumafonds.
Ethics approval Netherlands, CCMO: NL34124.041.10.
Provenance and peer review Not commissioned; externally peer reviewed.
To cite Enders FB, Delemarre EM, Kuemmerle-Deschner J, et al. Ann Rheum Dis
2015;74:315–317.
Received 15 July 2014
Revised 12 September 2014
Accepted 13 September 2014
Published Online First 30 September 2014
Ann Rheum Dis 2015;74:315–317. doi:10.1136/annrheumdis-2014-206287
REFERENCES
1 Robinson AB, Reed AM. Clinical features, pathogenesis and treatment of juvenile and
adult dermatomyositis. Nat Rev Rheumatol 2011;7:664–75.
2 Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune
diseases: updated guidelines of the European Group for Blood and Marrow
Transplantation. Bone Marrow Transplant 2012;47:770–90.
3 van Wijk F, Roord ST, Vastert B, et al. Regulatory T cells in autologous stem cell
transplantation for autoimmune disease. Autoimmunity 2008;41:585–91.
4 Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem
cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol
2010;39:88–92.
5 Bellutti Enders F, van Wijk F, Scholman R, et al. CXCL10, TNFR2 and Galectin-9
correlate with disease activity in Juvenile Dermatomyositis. Arthritis Rheumatol
2014;66:2281–9.
6 Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif ) ligand (CXCL)10
in autoimmune diseases. Autoimmun Rev 2014;13:272–80.
7 de Kivit S, Kraneveld AD, Knippels LM, et al. Intestinal epithelium-derived galectin-9
is involved in the immunomodulating effects of nondigestible oligosaccharides.
J Innate Immun 2013;5:625–38.
8 Hirashima M, Kashio Y, Nishi N, et al. Galectin-9 in physiological and pathological
conditions. Glycoconj J 2004;19:593–600.
9 Imaizumi T, Kumagai M, Sasaki N, et al. Interferon-gamma stimulates the expression
of galectin-9 in cultured human endothelial cells. J Leukoc Biol 2002;72:486–91.
Antibodies to domain I of β-2-glycoprotein
I and IgA antiphospholipid antibodies in
patients with ‘seronegative’ antiphospholipid
syndrome
The standard serological tests included in the classiﬁcation cri-
teria1 for antiphospholipid syndrome (APS) are those to detect
immunoglobulin G (IgG) and IgM antibodies to cardiolipin
(aCL) or β-2-glycoprotein I (anti-β2GPI) and the lupus anti-
coagulant. It is increasingly recognised, however, that some
patients have typical thrombotic and non-thrombotic features of
APS but test repeatedly negative in these routinely used assays. It
has been suggested that these patients have the so-called sero-
negative APS (SN-APS).2 In a retrospective study, there were no
signiﬁcant differences in clinical manifestations between 87
patients with seropositive APS and 67 with SN-APS.3 Several
authors have suggested that in these ‘seronegative’ patients,
clinically relevant antibodies can be detected by looking for dif-
ferent isotypes, particularly IgA2 and/or different antigen speciﬁ-
city4 or by using different techniques4 5 than those of the routine
assays. In a recent paper, 79% of 24 patients with SN-APS had
serum antibodies detectable by such strategies.5 There is consid-
erable evidence that IgA antiphospholipid antibody tests may be
a useful diagnostic tool in APS.6 Antibodies to domain I (DI) of
β2GPI have attracted particular interest as they are strongly
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associated with thrombosis.7–9 No formal analysis of anti-DI
antibodies (of any isotype) or IgA antiphospholipid antibodies in
patients with SN-APS has been reported.
Serum samples from 80 patients with APS (40 with seroposi-
tive APS fulﬁlling classiﬁcation criteria1 and 40 with SN-APS
fulﬁlling clinical but not serological criteria) from St Thomas’
Hospital (STH) and 200 healthy controls were tested at
University College London (UCL) in nine ELISAs—IgG, IgM
and IgA for each of aCL, anti-β2GPI and anti-DI. ELISAs were
carried out blind to the clinical and serological information
from STH using methods published previously10 with appropri-
ate modiﬁcations to detect IgA. We deﬁned the cut-off for a
positive result in each assay as the 99th centile of the healthy
population.
Clinical features of the patients are shown in table 1 and
results of the ELISAs in table 2. For ease of interpretation,
table 2 groups the four criteria tests used in routine clinical prac-
tice (IgG aCL, IgM aCL, IgG anti-β2GPI and IgM anti-β2GPI)
together at the top and the non-standard ELISAs (all anti-DI,
IgA aCL and IgA anti-β2GPI) below. In the seropositive APS
group, we found large numbers of samples that tested positive
in the ﬁve non-criteria ELISAs. Thus 62.5% were positive in at
least one of these assays. In the SN-APS group, we found no
samples positive in the standard assays (thus 100% agreement
with STH in tests at UCL done blind to STH results) but four
(10%) were positive in one of the non-standard ELISAs.
In conclusion, this blinded serological analysis of seropositive
and SN-APS cohorts conﬁrms that anti-DI, IgA aCL or IgA
anti-β2GPI antibodies, while present in a signiﬁcant proportion
of seropositive patients with APS, may also pick up a small pro-
portion of patients with SN-APS. In this study, the IgG anti-DI
assay had the highest pick-up rate (despite samples testing nega-
tive for anti-β2GPI), which is interesting given the accumulating
evidence that IgG anti-DI antibodies are important in the patho-
genesis of APS.7–10
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Table 1 Clinical features of patients in the study
APS group SN-APS group
Number in study 40 40
Gender
Male 4 0
Female 36 40
Mean age at sample 45.3 46.1
Diagnosis
PAPS 22 N/A
SLE/APS 18 N/A
SN-PAPS N/A 35
SN-APS/SLE N/A 5
Thrombosis 34 25
Venous 19 12
Arterial 15 13
None 6 15
Pregnancies?
Yes 33 39
No 3 1
N/A 4 0
Pregnancy morbidity 23 35
Miscarriage 12 29
Stillbirth 19 25
Prematurity 4 7
Preeclampsia 7 10
None 17 5
LA positivity
Yes 27 0
No 13 40
LA, lupus anticoagulant; PAPS, Primary Antiphospholipid Syndrome; SLE, systemic
lupus erythematosus; SN-APS, seronegative antiphospholipid syndrome.
Table 2 ELISA results
Seropositive
APS (n=40)
SN-APS
(n=40)
Standard ELISAs
No. (%) testing positive for IgG anti-CL 18 (45%) 0
No. (%) testing positive for IgG
anti-β2GPI
6 (15%) 0
No. (%) testing positive for IgM anti-CL 4 (10%) 0
No. (%) testing positive for IgM
anti-β2GPI
9 (22.5%) 0
Anti-DI ELISAs
No. (%) testing positive for IgG anti-DI 11 (27.5%) 3 (7.5%)*
No. (%) testing positive for IgM anti-DI 9 (22.5%) 0
No. (%) testing positive for IgA anti-DI 7 (17.5%) 0
Other IgA ELISAs
No. (%) testing positive for IgA anti-CL 12 (30%) 0
No. (%) testing positive for IgA
anti-β2GPI
8 (20%) 1 (2.5%)*
The cut-off for positive in each assay was defined as 99th centile of the healthy
control population.
*The titres of IgG anti-DI in the three positive patients were 16 absorbance units
(AU), 15.3 AU and 22.2 AU respectively compared with the positive cut-off of 10 AU.
The titre of IgA anti-β2GPI in the one positive patient was 16 AU compared with a
positive cut-off of 9 AU.
anti-β2GPI, anti-β-2-glycoprotein; CL, cardiolipin; DI, domain I; Ig, immunoglobulin;
SN-APS, seronegative antiphospholipid syndrome.
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